BD1031
BD1031
BD1031 (/biːdiː/ /wʌn/ /oʊ/ /θriː/ /wʌn/), also known as BD-1031 or BD 1031, is a pharmacological compound with potential therapeutic applications. The term "BD1031" is derived from the compound's identification code in the pharmaceutical industry.
Pharmacology
BD1031 is a sigma receptor antagonist, specifically targeting the sigma-1 receptor. Sigma receptors are a unique class of intracellular proteins that have been implicated in various disease states, including cancer, neurodegenerative diseases, and psychiatric disorders.
BD1031 has been shown to have potential therapeutic effects in preclinical studies, particularly in the treatment of neuropathic pain and drug addiction. However, further research is needed to fully understand the compound's mechanisms of action and potential therapeutic applications.
Etymology
The term "BD1031" is a code name used in the pharmaceutical industry to identify specific compounds during the drug development process. The "BD" prefix is typically assigned to compounds developed by a specific company or research group, while the "1031" suffix is a unique identifier for the compound.
Related Terms
External links
- Medical encyclopedia article on BD1031
- Wikipedia's article - BD1031
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski